IP GROUP
Oxford, UK, 20 February 2015 - Summit Therapeutics plc (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, is pleased to confirm that the Company has changed its name from Summit Corporation plc to Summit Therapeutics plc. This name change took effect following approval from shareholders at the General Meeting of the Company held on 19 February 2015, and the Company expects this change to be reflected on the London Stock Exchange system from the 23 February 2015.
The Company's TIDM ('ticker') on the London Stock Exchange in respect of the Company's Ordinary shares is 'SUMM' and remains unchanged. All share certificates in the name of Summit Corporation plc will remain valid. As and when transactions take place on shareholdings going forward, share certificates will be issued in the name of Summit Therapeutics plc.
- END -
About Summit Therapeutics
Summit is a drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski (US office)
Tel: +44 (0)1235 443 951/+1 617 294 6607
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson
Tel: +44 (0)20 7148 7900
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer
Tel: +44 (0)20 7496 3000
Peckwater PR
(Financial public relations, UK)
Tarquin Edwards
Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk
MacDougall Biomedical Communications
(US media contact)
Michelle Avery
Tel: +1 781 235 3060
mavery@macbiocom.com
|
distributed by
|
